Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane Model

Nutrition and Cancer

Volumn 52, Issue 1, 2005, Pages 59-65

  Mousa, Sarah S ^a   Mousa, Shaymaa S ^b   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; FIBROBLAST GROWTH FACTOR 2; PROTEIN P53; RESVERATROL;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHEMOPROPHYLAXIS; CHICK EMBRYO; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; FIBROSARCOMA; HUMAN; HUMAN CELL; IMMUNOASSAY; NONHUMAN; THROMBOCYTE; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL LINE; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLONIC NEOPLASMS; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; FIBROSARCOMA; FLAVONOIDS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET AGGREGATION INHIBITORS; STILBENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 24144443795     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/s15327914nc5201_8     Document Type: Article

References (34)

1. Moore RD and Pearson TA: Moderate alcohol consumption and coronary artery disease. Lancet 338, 985-992, 1991.
2. World Health Organization: The WHO Monica Report: a worldwide monitoring system for cardiovascular diseases. In World Health Statistics Annual. Geneva, Switzerland: WHO, 1989; pp. 27-59.
3. Shanmuganayagam D, Beahm MR, Osman HE, Krueger CG, et al.: Grape seed and grape skin extracts elicit a greater antiplatelet effect when used in combination than when used individually in dogs and humans. J Nutr 132, 3592-3598, 2002.
4. Davis MJ and Thomas A: Thrombosis and acute coronary artery lesions in sudden cardiac death. N Engl J Med 310, 113-137, 1984.
5. Kimura Y and Okuda H: Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung in Lewis lung carcinoma bearing mice. J Nutr 131, 1844-1849, 2001.
6. Breier G and Risau W: The role of vascular endothelial growth factors in blood vessel formation. Trends Cell Biol 6, 454-456, 1996.
7. Breier G, Damert A, Plate KH, and Risau W: Angiogenesis in embryos and ischemic diseases. Thromb Haemost 78, 678-683, 1997.
8. Anzano MA, Rieman D, Prichett W, Bowen-Pope DF, and Grieg R: Growth factor production by human colon carcinoma cell lines. Cancer Res 49, 2898-2904, 1989.
9. Basilico C and Moscatelli D: The FGF family of growth factors and oncogenes. Adv Cancer Res 59, 115-165, 1992.
10. Bikfalvi A, Klein S, Pintucci G, and Rifkin DB: Biological roles of fibroblast growth factor-2. Endocrinol Rev 18, 26-45, 1997.
11. Chopra V, Dinh TV, and Hannigan EV: Serum levels of interleukins, growth factors and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol 123, 167-172, 1997.
12. Czubayko F, Liaudet-Coopman ED, and Aigner A: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3, 1137-1140, 1997.
13. Folkman J: Angiogenesis in cancer, rheumatoid and other disease. Nat Med 1, 27-31, 1995.
14. Yilmaz Y and Toledo RT: Major flavonoids in grape seeds and skins: antioxidant capacity of catechin, epicatechin, and gallic acid. J Agric Food Chem 52, 255-260, 2004.
15. Burns J, Yokota T, Ashihara H, Lean ME, and Crozier A: Plant foods and herbal sources of resveratrol. J Agric Food Chem 50, 3337-3340, 2002.
16. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, et al.: Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med 113 Suppl 9B, 71S-88S, 2002.
17. Park EJ and Pezzuto JM: Botanicals in cancer chemoprevention. Cancer Metastasis Rev 21, 231-255, 2002.
18. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24, 2783-2840, 2004.
19. Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, et al.: Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J 17, 2339-2341, 2003.
20. Kong AN, Yu R, Hebbar V, Chen C, Owuor E, et al.: Signal transduction events elicited by cancer prevention compounds. Mutat Res 480-481, 231-241, 2001.
21. Fulda S and Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64, 337-346, 2004.
22. Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, et al.: Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′-tetramethoxystilbene. Br J Cancer 90, 736-744, 2004.
23. Yang CS, Landau JM, Huang MT, and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21, 381-406, 2001.
24. Zhou S, Koh HL, Gao Y, Gong ZY, and Lee EJ: Herbal bioactivation: the good, the bad and the ugly. Life Sci 74, 935-968, 2004.
25. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al.: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24, 2783-2840, 2004.
26. Tseng SH, Lin SM, Chen JC, Su YH, Huang HY, et al.: Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res 10, 2190-2202, 2004.
27. Lin MT, Yen ML, Lin CY, and Kuo ML: Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 64, 1029-1036, 2003.
28. Cao Y, Cao R, and Brakenhielm E: Antiangiogenic mechanisms of diet-derived polyphenols. J Nutr Biochem 13, 380-390, 2002.
29. Brooks PC, Clark RAF, and Cheresh D: Requirement of vascular integrin avb3 for angiogenesis. Science 264, 569-571, 1994.
30. Sangha S, Yao M, and Wolfe MM: Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgrad Med J 81, 223-227, 2005.
31. Lotan Y, Cadeddu JA, Lee JJ, Roehrborn CG, and Lippman SM: Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol 23, 1911-1920, 2005.
32. Gralow JR: Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 89 Suppl 1, S9-S15, 2005.
33. Fassina G, Vene R, Morini M, Minghelli S, Benelli R, et al.: Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 10, 4865-4873, 2004.
34. Falanga A: Mechanisms of thrombosis in cancer. Thromb Res 115 Suppl 1, 21-24, 2005.